Lowering Apo B works
- Stefan Hartmann, PA-C
- 5 days ago
- 2 min read
The data for lowering ApoB (via statins, ezetimibe, PCSK9i, etc.) is rock-solid and backed by decades of high-quality research. The idea that high ApoB is “fine if you’re lean and fit” (e.g. LMHR/keto crowd) is still just a hypothesis with weak, conflicting support.
✅ Evidence for Lowering ApoB
-Plaque regression trials (GLAGOV, ASTEROID, SATURN, HUYGENS): Intensive lowering (ApoB often <65 mg/dL) consistently shows plaque regression, stabilization, thicker fibrous caps, and reduced lipid content. Lower ApoB = more benefit, even after adjusting for LDL-C.
Causal proof: Massive Mendelian randomization studies, genetic data (FH), and meta-analyses of >2 million people confirm ApoB particles are directly causal in atherosclerosis. “The lower, the better” holds down to very low levels.
- Outcomes: Fewer events when ApoB drops. This is foundational cardiology, not fringe.
Mechanistically: Fewer ApoB particles = less cholesterol delivery into artery walls = less inflammation & plaque progression.
My results with 5mg Rosuvastatin and 10mg ezetimibe were winning an ITF M1000 event and perfect lipid and inflammation markers.
❌ “High ApoB is benign if lean/fit”
This relies heavily on small, short-term observational data like re-analyzed KETO-CTA (~100 people, very high ApoB, low baseline plaque, ~1 year follow-up). Some stability seen, but:
- No control group
- Short duration
- Narrow high-ApoB range (can’t test causality)
- Methodological issues
Some interpretations even showed worsening of plaque in such a short study in some participants.
Broader genetic & epidemiologic evidence shows lifelong high ApoB increases risk regardless of leanness. Metabolic health helps overall risk but does not fully cancel ApoB’s causal effect.
The Key Asymmetry
Lowering ApoB has direct, replicable proof of reversing disease in arteries.
The “it’s fine if you’re shredded” claim rests on absence of strong signal in one atypical short study.
Bottom line: Metabolic health is great, but the weight of evidence strongly favors keeping ApoB low for minimal lifetime cardiovascular risk. Betting against it long-term is risky when proven tools exist.
(What’s your ApoB? Drop it below 👇)
The article about lowering Apo B was informative because it explains why this marker is becoming so important for understanding heart health. I remember reading a similar health study and realizing there was much more to cardiovascular risk than cholesterol alone. While organizing my notes, I turned to assignment editing Service UK to make my explanations clearer. It helped me understand how small health indicators can have a big impact on long-term wellbeing.